News
10/07/08

Q2 2008 sales up 18%

1st half-year sales up 16%, revision upwards of 2008 sales growth...

24/06/08

Obtention of the market authorization in Germany for Oralair® Grasses

Stallergenes has been granted with the market authorization in Germany for...

24/06/08

Video interview of Albert Saporta

View the interview of Stallergenes CEO

Last update: 24/06/2008

STALLERGENES is a European biopharmaceutical laboratory specialising in the treatment by desensitisation of allergy-related respiratory conditions.

The Group's activities focus on research into allergy, and the development, production and distribution of allergen extracts for the curative treatment of allergic rhinitis and asthma.